The study used CRISPR/Cas9 technology to knock out SLFN11, and the results showed that knockout significantly inhibited the proliferation and neurosphere formation ability of GBM cells, accompanied by downregulation of the expression of precursor cell/stem cell marker genes (such as NES, SOX2, and CD44), indicating that SLFN11 deficiency weakened tumor stemness. The gene discussed is SLFN11; the disease is neoplasm.